Despite the expectations that the legal California cannabis market would rank amongst the highest in the world, a research agency has lowered its sale projections for the state by US$2 billion.

New Frontier Data, a firm issuing reports on business intelligence for the cannabis space announced on Monday (May 22) it has lowered the sales projection it previously held for the state from US$3.8 billion to US$1.9 billion due to “lower than expected cannabis excise-tax revenues for Q1 2018.”


Giadha Aguirre De Carcer, New Frontier Data founder and CEO said in the statement that the adult-use regulations in the state have made it “more difficult than anticipated” to establish the legal market compared to the existing illegal operations.

“Given the number of local government bans on cannabis businesses, we are not seeing the same kind of conversion rates that we have seen in other legal markets,” Aguirre De Carcer said.

According to New Frontier Data, California collected US$33.6 million in excise-tax revenues between January 1 and March 31, “which put them significantly behind pace to meet original expectations for collecting US$175 million within the first six months of 2018,” the agency wrote.

California sales projection lowers to over US$4 billion in 2025

This decline has caused the firm to now reevaluate its estimates all the way up to 2025. Instead of the originally forecasted US$6.7 billion in sales for the state, New Frontier Data now calculates that value to reach US$4.72 billion by 2025.

According to the statement, New Frontier Data evaluated two aspects when it came to rebalancing its projection. The firms’ analysts redefined what exactly a legal medical patient is while lowering the conversation rate for black market consumers transitioning to legal ones.

New Frontier Data estimates the total value for 2018 in the cannabis legal market will be US$1.92 billion and it is expected to grow at a compound annual growth rate (CAGR) of 13.7 percent from now until 2025.

The research firm is also expecting to see a 5.4 percent decline in the medical market throughout 2025, reaching a value of US$760 million, compared to the US$1.12 billion estimated current value.

During the same period, adult use sales are projected to grow at a “25.5 [percent] CAGR, from US$805 million to US$3.96 billion,” New Frontier Data wrote.

In February, Business Insider wrote on a BDS Analytics report placing its estimates for the California cannabis market at US$3.7 billion in 2018 and US$5.1 billion in 2019.

Statista, a provider of market and consumer data, offered its own prediction for the growth of the cannabis industry, projecting the marijuana sales value would reach approximately US$6.59 billion in California in 2025.

A new potential roadblock for legal consumers is starting on July 1 when cannabis producers in California will be required to obtain a seal of approval from a verified testing facility.

William Waldrop, CEO of EVIO Labs (OTCQB:EVIO) told the Investing News Network any cannabis product sold in California dispensaries is expected to have been tested and obtained a certificate confirming it.

Investor takeaway

While market prediction isn’t an exact fact, especially with potential catalysts such as federal decriminalization of the drug in the US, this projection does indicate the volatility of the cannabis industry.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less